Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Subscribe To Our Newsletter & Stay Updated